Abiopharma

🔍 Kelderman Kim (Director)

Company: BIO-TECHNE Corp (TECH)

Report Date: 2026-08-15

Detailed Transactions and Holdings:

• Acquired 21,470 shares of Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 93,583.00 | transaction_form_type: 4
• Sold 10,821 shares of Common Stock at $72.4 per share (Direct)
  Date: 2026-08-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 82,762.00 | transaction_form_type: 4
• Sold 554 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,319.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Sold 8,319 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Sold 22,389 shares of Performance Stock Options (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-15 | Code: D | Expires: 2030-08-15 | equity_swap_involved: 0 | shares_owned_after: 1,492.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 588 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,835.00 | transaction_form_type: 4 | Footnotes: F2, F7, F7
• Sold 8,835 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F7, F7
• Sold 24,324 shares of Performance Stock Options (Right to Buy) at $68.54 per share (Derivative)
  Date: 2026-08-15 | Code: D | Expires: 2031-02-01 | equity_swap_involved: 0 | shares_owned_after: 1,621.00 | transaction_form_type: 4 | Footnotes: F8
• Sold 8,543 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,544.00 | transaction_form_type: 4 | Footnotes: F2, F11, F11
• Sold 11,785 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,569.00 | transaction_form_type: 4 | Footnotes: F2, F14, F14
• Holds 115,724 shares of Stock Option (Right to Buy) at $66.97 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2027-08-05 | shares_owned_after: 115,724.00 | Footnotes: F1
• Holds 25,944 shares of Stock Option (Right to Buy) at $120.46 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2028-08-06 | shares_owned_after: 25,944.00 | Footnotes: F1
• Holds 28,940 shares of Stock Options (Right to Buy) at $94.52 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2029-08-15 | shares_owned_after: 28,940.00 | Footnotes: F1
• Holds 29,391 shares of Stock Options (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2030-08-15 | shares_owned_after: 29,391.00 | Footnotes: F5
• Holds 38,252 shares of Stock Options (Right to Buy) at $52.83 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2030-11-01 | shares_owned_after: 38,252.00 | Footnotes: F6
• Holds 51,890 shares of Stock Options (Right to Buy) at $68.54 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2031-02-01 | shares_owned_after: 51,890.00 | Footnotes: F9
• Holds 51,261 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: H | shares_owned_after: 51,261.00 | Footnotes: F2, F10, F10
• Holds 69,061 shares of Stock Options (Right to Buy) at $74.91 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2034-08-15 | shares_owned_after: 69,061.00 | Footnotes: F12
• Holds 70,708 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: H | shares_owned_after: 70,708.00 | Footnotes: F2, F13, F13
• Holds 90,441 shares of Stock Options (Right to Buy) at $53.6 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2035-08-15 | shares_owned_after: 90,441.00 | Footnotes: F15

Footnotes:

• F1: Fully exercisable.
• F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
• F3: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited.
• F4: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,492 performance options. The remainder of the performance options were forfeited.
• F5: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
• F6: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
• F7: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited.
• F8: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,621 performance options. The remainder of the performance options were forfeited.
• F9: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
• F10: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F11: 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
• F12: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
• F13: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F14: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
• F15: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.